Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")

Study:

Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD")

Rationale:

n/a

Purpose:

The purpose of this study is to evaluate the safety, effectiveness, and side effects of the CryoSpray AblationTM System (CryoSpray AblationTM, "CSA" or "cryospray therapy") to treat benign airway disease in the lung using liquid nitrogen sprayed through a catheter via flexible fiber optic bronchoscopy (FFB)

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Benign Airway Disease
Sarcoidosis
Wegener`s Granulomatosis
Rhinoscleroma
Recurrent Respiratory Papillomatosis(RRP)
Device: CryoSpray Ablation (tm) Phase 4

Verified by CSA Medical, Inc. May, 2009

Sponsored by: CSA Medical, Inc.
Information provided by: CSA Medical, Inc.
ClinicalTrials.gov identifier: NCT00747461

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Michael Machuzak, M.D.., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site